ALNY - candlestick chart analysis of Alnylam Pharmaceuticals Inc.

Popular stocks today

AAPL DIA FSLR GLD HDB INFY KWEB META MSFT NFLX NVDA PLTR QQQ SCHD SOXL SPY TQQQ TSLA VOO VTI

Earnings:APR 22

Membership
- Log In
- Log Out
- Sign Up
- About HotCandlestick
- Benefits
- Help
Candlestick Charts
Chart Education
Trading Tools
Opportunities
External Links

Official PayPal Seal

As Seen In...

The Complete Guide to Using Candlestick Charting: How to Earn High Rates of Return safely

End of day quotes updated Tue Apr 22 15:50 CST
🏠

⎙

🔍

◄ Daily Pattern ► ◄ Weekly Pattern ► ◄ Monthly Pattern ► ◄ Quarterly Pattern ►
Bearish Three Inside Down Bearish Harami Bullish Doji Star Bullish Engulfing
04-Apr-2025 01-Mar-2024 28-Mar-2024 30-Sep-2022
10.4 strength -86.8 strength 55.3 strength -567.2 strength

ALNY	SPY
1.7 0.9 -12.3 -12.3 0.6	2.6 0.2 -5.7 -5.7 -10.0
% Price Gain WTD Performance (%) MTD Performance (%) QTD Performance (%) YTD Performance (%)
SPY tracks S&P 500 index.

ALNY News
17-Apr-2025 7:00 AM CST - Business Wire Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2025 results as well as expectations for the future via conference call on Thursday, May 1, 2025 at 8:30 am ET. A live audio webcast of the
1-Apr-2025 7:00 AM CST - Business Wire Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare Conference on Tuesday, April 8, 2025 at 11:45 am ET. A live audio webcast of the presentation will be available on the Investors section of the Companys website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.
20-Mar-2025 4:54 PM CST - Business Wire Alnylam Announces FDA Approval of AMVUTTRA (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failu
11-Mar-2025 7:00 AM CST - Business Wire Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 3:00 pm ET. A live audio webcast of the presentation will be available on the Investors section of the Companys website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. About Alnylam Pharm
13-Feb-2025 7:00 AM CST - Business Wire Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024 and reviewed recent business highlights. 2024 was another year of impressive execution for Alnylam, generating product revenues of over $1.6 billion, reflecting growth of 33% compared to 2023, and highlighting the strength of our base business in hATTR-PN and Rare in
30-Jan-2025 7:00 AM CST - Business Wire Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2024 on Thursday, February 13, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2024 results as well as expectations for the future via conference call on Thursday, February 13, 2025 at 8
12-Jan-2025 3:00 PM CST - Business Wire Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2024 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. In addition, the Company provided 2025 net product revenue, non-GAAP operating income profitability, and pipeline goals guidance. Alnylams commercial and clinical achievements in 2024 position us very well for another transformative yea
6-Jan-2025 7:00 AM CST - Business Wire Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. As part of the presentation, the Company will discuss unaudited fourth quarter and full year 2024 global net product revenues
27-Nov-2024 6:00 AM CST - Business Wire Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 11:00 am ET at the Lotte New York Palace Hotel in New York City. A live audio webcast of the presentation will be available on the Investors section of the Companys website at www.alnylam.com/events. A replay will be available

Disclaimer Privacy Contact

Copyright © 2001-2025, All rights reserved.
HotCandlestick.com, LLC

ALNY News
17-Apr-2025 7:00 AM CST - Business Wire Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2025 results as well as expectations for the future via conference call on Thursday, May 1, 2025 at 8:30 am ET. A live audio webcast of the
1-Apr-2025 7:00 AM CST - Business Wire Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare Conference on Tuesday, April 8, 2025 at 11:45 am ET. A live audio webcast of the presentation will be available on the Investors section of the Companys website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.
20-Mar-2025 4:54 PM CST - Business Wire Alnylam Announces FDA Approval of AMVUTTRA (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failu
11-Mar-2025 7:00 AM CST - Business Wire Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 3:00 pm ET. A live audio webcast of the presentation will be available on the Investors section of the Companys website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. About Alnylam Pharm
13-Feb-2025 7:00 AM CST - Business Wire Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024 and reviewed recent business highlights. 2024 was another year of impressive execution for Alnylam, generating product revenues of over $1.6 billion, reflecting growth of 33% compared to 2023, and highlighting the strength of our base business in hATTR-PN and Rare in
30-Jan-2025 7:00 AM CST - Business Wire Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2024 on Thursday, February 13, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2024 results as well as expectations for the future via conference call on Thursday, February 13, 2025 at 8
12-Jan-2025 3:00 PM CST - Business Wire Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2024 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. In addition, the Company provided 2025 net product revenue, non-GAAP operating income profitability, and pipeline goals guidance. Alnylams commercial and clinical achievements in 2024 position us very well for another transformative yea
6-Jan-2025 7:00 AM CST - Business Wire Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. As part of the presentation, the Company will discuss unaudited fourth quarter and full year 2024 global net product revenues
27-Nov-2024 6:00 AM CST - Business Wire Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 11:00 am ET at the Lotte New York Palace Hotel in New York City. A live audio webcast of the presentation will be available on the Investors section of the Companys website at www.alnylam.com/events. A replay will be available